Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$6.79+0.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Broken: Primary pillar broken — Achieve double-digit revenue growth in 2026: FY26 revenue guidance $9.1M vs FY25 $45.0M (-80%) vs 10% target.
Cumberland aims for double-digit revenue growth in 2026. It sold assets for $100 million. The company is working to join Apotex's U.S. branded business. These moves could help fix its losses.
Cumberland lost money last year and missed earnings twice. Key sales leaders left recently. Litigation and credit issues add risks. Revenue is expected to shrink slightly next year.
The price is about 13% above our fair value near $5.7. Analysts expect almost no revenue growth. We see some upside if growth returns.
Breaks if: Integration delays or failures reported in next 4 quarters
Breaks if: New significant litigation or large legal losses occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation. CPIX is currently loss-making and has mixed management execution, but it is focusing on advancing its drug development and integrating its recent acquisition.
The market seems to have priced in a justified valuation with a low expectations gap. However, CPIX is trading at a premium compared to its peers, indicating that some positive developments may already be anticipated.
Fundamentals are expected to remain weak in the near term, given the company's loss-making status and recent financial performance. Management's focus on drug development and integration efforts may provide some stability, but risks remain elevated.
The long-term thesis hinges on the outcomes of CPIX's drug development programs and the integration of its acquisition. Additionally, external factors like sector performance and economic conditions will play a significant role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. CPIX experienced a sharp drop of 22% in a single session. This price movement suggests the market is repricing the reasons to own it. Recent financial performance remains well below its industry peers, which is concerning.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 5% in FY26
CPIX is navigating a challenging environment with mixed signals from management and financial performance. The next few quarters will be crucial for assessing its long-term potential. Not investment advice.